These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33162515)

  • 1. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the treatment of polycythemia vera.
    Duek A; Berla M; Ellis MH
    Leuk Lymphoma; 2022 Aug; 63(8):1801-1809. PubMed ID: 35387553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
    Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
    Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
    Stein BL; Oh ST; Berenzon D; Hobbs GS; Kremyanskaya M; Rampal RK; Abboud CN; Adler K; Heaney ML; Jabbour EJ; Komrokji RS; Moliterno AR; Ritchie EK; Rice L; Mascarenhas J; Hoffman R
    J Clin Oncol; 2015 Nov; 33(33):3953-60. PubMed ID: 26324368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat polycythemia vera.
    Passamonti F
    Blood; 2012 Jul; 120(2):275-84. PubMed ID: 22611155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
    Kuykendall AT
    Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
    Maffioli M; Mora B; Passamonti F
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
    Kremyanskaya M; Mascarenhas J; Hoffman R
    Expert Opin Pharmacother; 2015 Jun; 16(8):1185-94. PubMed ID: 25873215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera: aspects of its current diagnosis and initial treatment.
    Silver RT; Abu-Zeinah G
    Expert Rev Hematol; 2023 Apr; 16(4):253-266. PubMed ID: 37013802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.